Papillary renal cell carcinoma: A review of the current therapeutic landscape
作者： Giulia Courthod , Marcello Tucci , Massimo Di Maio , Giorgio V. Scagliotti
DOI: 10.1016/J.CRITREVONC.2015.05.008
关键词:
摘要: Renal cell carcinoma (RCC) is the most common cancer of kidney and accounts for 2-3% all adult malignancies. Clear represents histologic subtype, while papillary Cell Carcinoma (pRCC) 10-20% renal cancers. While inactivation VHL gene can be found in majority clear carcinomas, different molecular mechanisms are involved into pRCC biology. Mutations MET oncogene an essential step pathogenesis hereditary forms, but they only a small rate sporadic cases. Several agents, including anti-VEGF drugs mTOR inhibitors, possible options treatment advanced metastatic pRCC, following demonstration efficacy obtained clinical trials RCC subtypes. However, data specifically subgroup patients affected by limited not conclusive. ongoing evaluating targeted therapy form. more rationale approaches based on studies would help improving outcome these patients. Among others, inhibitors immunotherapy promising new strategies disease. This review summarizes current knowledge tumorigenesis discusses recent with therapeutic agents.
elsevier.com
croh-online.com 参考文章(95)
I. Lubensky, H. Neumann, Zhengping Zhuang, L. Schmidt, K. Junker, G. Glenn, M. Jeffers, W. M. Linehan, G. Vande Woude, G. Weirich, M. Walther, B. Zbar, P. Choyke, Two North American Families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene Cancer Research. ,vol. 58, pp. 1719- 1722 ,(1998)
Irma Kluijt, H. Jelle Teertstra, Simon Horenblas, Jay Ryu, Daphne De Jong, Erin Reese, Jason Sluzevich, Birt-Hogg-Dubé Syndrome National Center for Biotechnology Information (US). ,(2009)
John N. Eble, Brett Delahunt, Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Modern Pathology. ,vol. 10, pp. 537- 544 ,(1997)
Feng Jiang, Jan Richter, Peter Schraml, Lukas Bubendorf, Thomas Gasser, Guido Sauter, Michael Jörg Mihatsch, Holger Moch, Chromosomal Imbalances in Papillary Renal Cell Carcinoma : Genetic Differences between Histological Subtypes American Journal of Pathology. ,vol. 153, pp. 1467- 1473 ,(1998) , 10.1016/S0002-9440(10)65734-3
Patrick Schöffski, Jorge A. Garcia, Walter M. Stadler, Thierry Gil, Eric Jonasch, Scott T. Tagawa, Melanie Smitt, Xinqun Yang, Kelly S. Oliner, Abraham Anderson, Min Zhu, Fairooz Kabbinavar, A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma BJUI. ,vol. 108, pp. 679- 686 ,(2011) , 10.1111/J.1464-410X.2010.09947.X
Andrew J. Wagner, John M. Goldberg, Steven G. DuBois, Edwin Choy, Lee Rosen, Alberto Pappo, James Geller, Ian Judson, David Hogg, Neil Senzer, Ian J. Davis, Feng Chai, Carol Waghorne, Brian Schwartz, George D. Demetri, Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer. ,vol. 118, pp. 5894- 5902 ,(2012) , 10.1002/CNCR.27582
Victor E. Reuter, Suresh C. Jhanwar, Frederick P. Li, William R. Fair, P. H. Rao, Q. Chen, Joseph C. Presti, Histopathological, cytogenetic, and molecular characterization of renal cortical tumors. Cancer Research. ,vol. 51, pp. 1544- 1552 ,(1991)
László Füzesi, Gerhard Jakse, Wolfgang Huber, Bastian Gunawan, Rolf-Hermann Ringert, Thekla Fritsch, Anja von Heydebreck, Cytogenetic and Morphologic Typing of 58 Papillary Renal Cell Carcinomas: Evidence for a Cytogenetic Evolution of Type 2 from Type 1 Tumors Cancer Research. ,vol. 63, pp. 6200- 6205 ,(2003)
Patrick H. Maxwell, Michael S. Wiesener, Gin-Wen Chang, Steven C. Clifford, Emma C. Vaux, Matthew E. Cockman, Charles C. Wykoff, Christopher W. Pugh, Eamonn R. Maher, Peter J. Ratcliffe, The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis Nature. ,vol. 399, pp. 271- 275 ,(1999) , 10.1038/20459
Betty Gardie, Audrey Remenieras, Darouna Kattygnarath, Johny Bombled, Sandrine Lefèvre, Victoria Perrier-Trudova, Pierre Rustin, Michel Barrois, Abdelhamid Slama, Marie-Françoise Avril, Didier Bessis, Olivier Caron, Frédéric Caux, Patrick Collignon, Isabelle Coupier, Carol Cremin, Hélène Dollfus, Catherine Dugast, Bernard Escudier, Laurence Faivre, Michel Field, Brigitte Gilbert-Dussardier, Nicolas Janin, Yves Leport, Dominique Leroux, Dan Lipsker, Félicia Malthieu, Barbara McGilliwray, Christine Maugard, Arnaud Méjean, Isabelle Mortemousque, Ghislaine Plessis, Bruce Poppe, Christelle Pruvost-Balland, Serena Rooker, Joelle Roume, Nadem Soufir, Michelle Steinraths, Min-Han Tan, Christine Théodore, Luc Thomas, Pierre Vabres, Emmanuel Van Glabeke, Jean-Baptiste Meric, Virginie Verkarre, Gilbert Lenoir, Virginie Joulin, Sophie Deveaux, Veronica Cusin, Jean Feunteun, Bin Tean Teh, Brigitte Bressac-de Paillerets, Stéphane Richard, None, Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma Journal of Medical Genetics. ,vol. 48, pp. 226- 234 ,(2011) , 10.1136/JMG.2010.085068